AXAHY — AXA SA
Price when we picked it (Mar 18, 2026)
$45.09
Target: $49.34 (+9.4%)
P/E Ratio
8.4
P/E Forward
8.7
Dividend
5.39%
Market Cap
$94.3B
EPS
$5.36
Consensus
Strong Buy
What they do
AXA is one of the largest insurers in the world. It operates in property and casualty insurance (cars, homes, liability), life and savings insurance, health insurance, and asset management. AXA XL is its global commercial/specialty lines arm. With 156,000 employees and presence in about 50 countries, it is a diversified financial giant.
Why we like it
Trades at just 8.7x forward price vs. profit — incredibly cheap for a dominant global insurer. Dividend (the cash they pay you) of 5.4% backed by a disciplined policy of 75% total payout (60% dividend + annual buybacks). The 'Unlock the Future' plan 2024-2026 targets high growth in earnings per share of 6-8%. Target return on equity of 14-16% and beta of just 0.65 — defensive growth with real upside.
Key Risk
Natural disasters due to climate change can significantly increase claim costs, especially in AXA XL. Complex regulation in over 50 jurisdictions.
This is educational and informational content, not financial advice. Always consult a qualified financial advisor before making investment decisions.
Vectorial Data picked AXAHY on Mar 18, 2026 at $45.09.
Full Research
AXA SA (AXAHY) — Full Research
Price: $45.09 | P/E: 8.4 | P/E Forward: 8.7 | Div Yield: 5.4% | Market Cap: $94.3B
What is AXA?
AXA SA is one of the largest insurers in the world and the #1 in Europe. Headquartered in Paris, France, it operates in about 50 countries with 92 million customers and 156,000 employees. It offers property, life, health insurance, and asset management.
Business Segments
| Segment | Description | Presence |
|---|---|---|
| France | Property & Casualty, life, health insurance — domestic market | France |
| Europe | Operations in Germany, Switzerland, Belgium, Italy, Spain, UK, Ireland | Continental Europe + UK |
| AXA XL | Commercial and specialty lines (reinsurance, large risks) | Global (mainly USA) |
| Asia | Life, health, P&C insurance | Japan, Hong Kong, Thailand |
| Africa & EME-LATAM | Emerging markets | Africa, Middle East, Latin America |
| AXA Investment Managers | Institutional asset management | Global |
2025 Results
| Metric | Value |
|---|---|
| Revenue | ~€110B+ |
| Underlying Earnings | Solid growth vs 2024 |
| ROE | ~15% (within the 14-16% target) |
| Solvency II Ratio | ~220% (very well capitalized) |
| Free Cash Flow | Strong organic generation |
Strategic Plan "Unlock the Future" 2024-2026
- EPS CAGR target: 6-8% (guiding to the high range for 2026)
- ROE target: 14-16%
- Total payout: 75% of profit (60% dividend + buybacks)
- Organic cash generation: €21B accumulated 2024-2026
- Focus: Growth in commercial P&C, digital platform, health and employee benefits
Capital Return — Very Generous
- Forward dividend: $2.44/share (5.4% yield)
- Policy: 75% total payout
- Annual buybacks complement the dividend
- Total shareholder yield: ~7-8% annual estimated
Analyst Analysis
| Metric | Value |
|---|---|
| Consensus | Strong Buy |
| Average Price Target | $49.34 |
| High Price Target | $58.26 |
| Low Price Target | $44.00 |
| Upside to Target | +9.4% |
Why Do We Like It?
- Forward price vs. profit of 8.7x — ridiculously cheap for Europe's #1 insurer
- Dividend of 5.4% — one of the highest in the portfolio, well covered
- 75% total payout — disciplined policy of returning money to shareholders
- Beta of 0.65 — less volatile than the market, defensive growth
- ROE of 14-16% — superior value generation
- Global diversification — 50 countries, 92M customers, multiple business lines
- €21B in cash generation over 3 years — cash machine
Risks
- Natural disasters — climate change increases frequency and severity of claims
- Complex regulation — operates in over 50 jurisdictions with different rules
- Borrowing costs — drops in rates can affect investment returns
- AXA XL big price swings — commercial/specialty lines are cyclical
- Exposure to emerging markets — political and currency risk
Research date: Mar 18, 2026 | Next review: Sep 2026
This is not financial advice.
This is not financial advice. Consult a certified financial advisor.
The author may hold positions in the securities discussed.
Past performance does not guarantee future results.